Amneal announces BLA submission of biosimilar candidate to XOLAIR
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal.
Amneal
Amneal gets FDA approval of sodium oxybate oral solution
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Amneal announces proposed refinancing of existing credit agreement
The proposed transactions are subject to market conditions and other factors, and there can be no assurance as to whether or when these transactions may be completed, or as to the actual size or terms of the transactions.